- Conditions
- Predicted Tauopathies, Including, Progressive Supranuclear Palsy, Frontotemporal Dementia With Parkinsonism Linked to Chromosome 17, Corticobasal Degeneration Syndrome, Progressive Nonfluent Aphasia
- Interventions
- davunetide (AL-108, NAP), Placebo nasal spray
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2019 · Synced May 21, 2026, 11:38 PM EDT